Embrace Precision Medicine. Improve Health.
How can you realize effective translational and reverse-translational research for precision medicine development? By leveraging multi-modal data from any drug development stage to generate scientific insights and make faster, data-informed decisions on the most suitable therapeutic targets, indications to pursue, and patients to enroll in clinical trials.
This is where Genedata comes in.
Our Customers
- Integrated Data. Available. Accessible.
- Faster Insights. More Impact.
- Data Governance. Secure. Controlled.
- GxP Validation. Simplified.
Integrated Data. Available. Accessible.
- Break data silos and bring together diverse data types across non-clinical, clinical, and real-world scenarios onto a single platform.
- Organize, control quality, process, and harmonize clinical, phenotype, image, biomarker, and multi-omics data automatically and efficiently.
- Accelerate time-to-insights by orchestrating data operations and enhancing collaboration between data engineering and science.
- Integrate ontologies and data standards to gain more insight across experiments and studies.
- Make annotated and harmonized datasets findable via a secure and intuitive user-friendly interface.
- Leverage deployment-ready automatic workflows to import data from commonly used public and commercial data sources—such as TCGA and Tempus—to validate in-house results.
Faster Insights. More Impact.
- Accelerate experiments in target discovery, PK, in vivo efficacy, safety, biomarker discovery, and patient stratification.
- Integrate proprietary R&D data across experiments with public and real-world data to make better-informed, data-driven decisions.
- Enable researchers with out-of-the-box, point-and-click solutions and domain-specific dashboards to easily analyze data.
- Empower data scientists and bioinformaticians to collaborate and perform big data analytics (using R, Python, etc.) within an integrated high-performance analytics environment including GPU support.
- Allow diverse research teams to collaborate, share data, results, and knowledge.
Data Governance. Secure. Controlled.
- Securely share data across projects and authorized team members, maintain its integrity, and control its consumption.
- Empower all data product generators to manage data access to protect confidential information on a GDPR-compliant platform that encrypts all sensitive data.
- Maintain a complete record of data manipulation and track all data activity while complying with regulatory requirements for clinical trial data protection.
- Identify and flag potential data inconsistencies and errors using built-in data quality checks and validation rules.
GxP Validation. Simplified.
- Benefit from a validation-ready system designed with built-in features for GxP environments and comprehensive validation support services that assist with implementation and documentation of the validation process.
- Save time through automated reports detailing the complete chain of custody, access control, controlled workflows, and data integrity checks.
- Access templates for computer system validation to simplify qualification tests.
- Maintain compliance and establish a robust, reproducible validation procedure.
Customer Stories
Unlocking Insights from Tempus Real-World Data
“Astellas Pharma uses Genedata Profiler to unlock insights from Tempus Real-World Data, enhancing oncology research with scalable bioinformatics and improved data discoverability.” Guoqiang Zhang, PhD, Astellas
Strategy for Immunotherapy Biomarker Identification
“We integrate large data sets to associate with clinical responses and evaluate markers. Genedata Profiler immensely helped with this.” Dr. Patrick Kaminker, MacroGenics.
Merck & Genedata Win Bio-IT World 2022 Award
Merck and Genedata Profiler win Bio-IT World 2022 Award for democratizing data, harmonizing analytics, and leveraging AI to accelerate biotherapeutics development and precision medicine.
Identifying Pediatric Crohn’s Biomarkers
“Partnering with Genedata, we’ve developed tailored analytical approaches to evaluate molecular features from 1000 patients, advancing prognostic tools for Crohn’s Disease and precision medicine for inflammatory bowel diseases.” Andres Hurtado-Lorenzo, PhD